Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New York-Presbyterian Hospital

www.nyp.org

Latest From New York-Presbyterian Hospital

Merck's Keytruda Monotherapy May Get Stuck With Small Role In First-line Lung Cancer

As results for KEYNOTE-042 are reported at ASCO, Merck's Roy Baynes says Keytruda plus chemotherapy is the standard of care in first-line non-small cell lung cancer, but Keytruda monotherapy is an option for those who don't tolerate chemo well and/or don't have very active disease.

ImmunoOncology Clinical Trials

US Heart Valve Treatments Market Fueled By New Transcatheter Valves

The US heart valve treatments market will reach $1.7 billion by 2019, driven by advances in percutaneous heart valve repair and replacement products and a growing number of competitors entering this space. With US sales of transcatheter aortic valve replacement systems set to almost triple in the next several years, the combined US market for products to treat heart valve disorders is expected to grow at a CAGR of 7.7%.

Medical Device Europe

In Atrial Fibrillation, SentreHEART Lassos An Advantage

SentreHEART is operating in one of the most promising device spaces in stroke: percutaneous left atrial appendage closure. Unlike early movers, SentreHEART doesn’t leave an implant behind in the heart, and its LARIAT procedure might have unique benefits in addressing not only the stroke risk that comes with atrial fibrillation, but also AF itself.

Medical Device

Vascular Interventional Devices: New Avenues For Growth

Manufacturers are finding it harder to innovate in the vascular interventional devices as market and regulatory pressures take their toll. New coronary drug-eluting stents face a difficult challenge with the high bar now set by existing devices, and there have been several recent disappointments in renal denervation, drug-coated balloons, and renal artery stenting; still there are some promising areas, with bioresorbable stents offering perhaps the best prospect among vascular therapies for future blockbuster status.

Medical Device
See All

Company Information

  • Industry
  • Services
  • Therapeutic Areas
  • Alias(es)
  • Presbyterian Hospital of New York
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • New York-Presbyterian Hospital
  • Senior Management
  • Frank Maddalena, SVP & COO
  • Contact Info
  • New York-Presbyterian Hospital
    Phone: (212) 305-2500
    622 West 168th Street
    New York, NY 10032-
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register